ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited
Your view on ASLN
Overview
What the company does, where it operates, and who runs it.
About ASLAN Pharmaceuticals Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Carl Alan Jason Morton Firth EMBA,
- Headquarters
- SG
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Carl Alan Jason Morton Firth EMBA,
- Headquarters
- SG
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.
It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ASLAN Pharmaceuticals Limited, and the rating behind it. ASLN last traded at $0.60; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ASLAN Pharmaceuticals Limited. Starting points for ASLAN Pharmaceuticals Limited: EPS -$10.75, beta 1.40 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ASLAN Pharmaceuticals Limited. ASLAN Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ASLAN Pharmaceuticals Limited. Trailing twelve-month EPS for ASLAN Pharmaceuticals Limited stands at -$10.75. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ASLAN Pharmaceuticals Limited. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ASLAN Pharmaceuticals Limited valued side by side against its closest peers. ASLAN Pharmaceuticals Limited is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ASLAN Pharmaceuticals Limited, and how their positions are changing. At a $777.1M market value, institutional positions materially move ASLAN Pharmaceuticals Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ASLAN Pharmaceuticals Limited executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ASLAN Pharmaceuticals Limited. ASLAN Pharmaceuticals Limited is a $777.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ASLAN Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ASLAN Pharmaceuticals Limited. Coverage tracks ASLAN Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.